{"id":541,"date":"2008-08-30T16:50:07","date_gmt":"2008-08-30T15:50:07","guid":{"rendered":"http:\/\/localhost\/new\/htb\/?p=541"},"modified":"2013-08-27T16:14:09","modified_gmt":"2013-08-27T16:14:09","slug":"new-us-pediatric-dosing-for-tipranavirr","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/541","title":{"rendered":"New US pediatric dosing for tipranavir\/r"},"content":{"rendered":"<p><strong>On June 23, 2008, FDA approved a new Aptivus (tipranavir) oral solution (100 mg\/mL). The product label has been updated to include dosing recommendations for pediatric patients 2-18 years of age.<\/strong><\/p>\n<p>In addition, information regarding oral and parenterally administered midazolam was updated in the Contraindication and Drug Interactions section.<\/p>\n<p>Source: FDA list serve (23 June 2008).<br \/>\n<a href=\"http:\/\/www.fda.gov\/oashi\/aids\/listserve\/listserve2008.html#062308\">http:\/\/www.fda.gov\/oashi\/aids\/listserve\/listserve2008.html#062308<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On June 23, 2008, FDA approved a new Aptivus (tipranavir) oral solution (100 mg\/mL). The product label has been updated to include dosing recommendations for pediatric patients 2-18 years of age. In addition, information regarding oral and parenterally administered midazolam &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-541","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=541"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/541\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}